Q. Are HepaLife shares
publicly traded? If so, where are they available? |
A. Yes, HepaLife Technologies, Inc. is
a developer of cell-based medical technologies, publicly traded
under the ticker symbol:
- HPLF on the OTCBB exchange in the USA
- WKN 500625 (ISIN: US42689P1049) in Germany
|
Q. What
is HepaLife’s CUSIP number? |
A. HepaLife’s CUSIP number is 42689P104
|
Q. How do investors acquire
HepaLife shares for their portfolios? |
A. Please see below for the following options:
- HPLF common shares can only be purchased through a registered
investment advisor, stockbroker, or financial services
firm and/or bank that provides share brokerage services.
- Shares may not be purchased directly through the Company
at this time.
- Should you or your broker require additional information,
kindly contact HepaLife Investor Relations at 1-800-518-4879
or by using our website
form (click here) to email us.
- Investor education information is available through the
Securities and Exchange Commission’s Office of Investor
Education at http://www.sec.gov/investor.shtml.
|
Q. Who is the Company’s
transfer agent? |
A. HepaLife’s transfer agent is Holladay
Stock Transfer, Inc.. The transfer agent is able to assist
investors who have misplaced, lost, or destroyed share certificates.
Should you or your broker need to get in touch with HepaLife’s
transfer agent, kindly refer to the contact information below:
Holladay Stock Transfer, Inc.
2939 N. 67th Place
Scottsdale, AZ 85251
Tel: (480) 481-3940 Fax: (480) 481-3941
|
Q. What are the Company’s
quarterly reporting periods and when is the fiscal year-end? |
A. HepaLife’s quarterly reporting periods
are as listed below:
- Q1 January 1 thru March 31
- Q2 April 1 thru June 30
- Q3 July 1 thru September 30
- Q4 October 1 thru December 31
- HepaLife’s fiscal year ends December 31
|
Q. When and where was
HepaLife Technologies, Inc. originally incorporated? |
| A. HepaLife Technologies,
Inc. was first incorporated as Zeta Corporation in the State
of Florida, effective October 21, 1997. |
Q. How can I receive updated
financial information on HepaLife? |
| A. HepaLife routinely files financial reports
and discloses financial information as per legal requirements
stipulated by the Securities Exchange Commission (SEC). The Company’s
filings may be viewed on this web site’s ‘SEC Filings’ section
or at the SEC web site at http://www.sec.gov. |
| |
Q. When and where does
the HepaLife annual general meeting take place? |
A. In accordance with SEC rules, HepaLife
shareholders are formally provided advance notice of the annual
general meeting (AGM) each year. The AGM time, location, agenda
and other information may be obtained by contacting the Company’s
Investor Relations department at 1-800-518-4879 or by using
our website form
(click here) to email us.
|
